Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin for Refractory Trigeminal Neuralgia
NCT02088632Phase 2Terminated
- Sponsor
- Thomas Jefferson University
- Start
- Mar 2014
- Primary completion
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of botulinum toxin type A in trigeminal neuralgia (TN), sponsored by Thomas Jefferson University. Started Mar 2014; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
trigeminal neuralgia (TN)
Beyond the preview
Go deeper on NCT02088632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02088632.